Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy

Hematology/Oncology Clinics of North America

Volumn 17, Issue 4, 2003, Pages 969-975

  Lu, M Janice ^a   Sorich, Joan ^a   Hazarika, Maitreyee ^a   Kim, Mimi ^a   Del Priore, Giuseppe ^b   Jacobs, Allan J ^b   Chiang, Chang ^a   Liu, Paul C ^b   Fusco, Eileen ^b   Curtin, John P ^b   Muggia, Franco M ^a,c  

^a NEW YORK UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BELLEVUE HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLOXURIDINE;

ADULT; AGED; BLOOD TOXICITY; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; INGUINAL LYMPH NODE; LUNG METASTASIS; LYMPH NODE METASTASIS; MORTALITY; NEUTROPENIA; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 10744227981     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00059-5     Document Type: Review

References (16)

1. Dedrick RL, Myers CE, Bungay PM, DeVita VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1-11.
2. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-5.
3. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-7.
4. McGuire WP. Intraperitoneal therapy for ovarian cancer: a sacrifice bunt. J Clin Oncol 2001;19:921-3.
5. Armstrong DK, Bundy BN, Baergen R, Lele SB, Copeland LJ, Walker J, et al. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172) [abstr 803]. Proc Am Soc Clin Oncol 2002;21:201a.
6. Muggia FM, Chan KK, Russell C, Colombo N, Speyer JL, Sehgal K, et al. Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2′-deoxyuridine. Cancer Chemother Pharmacol 1991;28(4):241-50.
7. Muggia FM, Liu PY, Alberts DS, Wallace DL, O'Toole RV, Terada KY, et al. Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy. Gynecol Oncol 1996;61:395-402.
8. Muggia FM, Jeffers S, Muderspach L, Roman L, Rosales R, Groshen S, et al. Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/ or carboplatin). Gynecol Oncol 1997;66(2):290-4.
9. Menczer J, Ben-Baruch G, Rizel S, Brenner H. Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission. Gynecol Oncol 1992;46(2):222-5.
10. De Gramont A, Demuynck B, Louvet C, Gonzalez-Canali G, Varette C, Pigne A, et al. Survival with intraperitoneal cisplatin in advanced ovarian cancer after second-look laparotomy. Am J Clin Oncol 1992;15(1):7-11.
11. Tarraza Jr HM, Boyce CR, Smith WG, Jones MA. Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy. Gynecol Oncol 1993;50(3):287-90.
12. Dufour P, Bergerat JP, Barats JC, Giron C, Duclos B, Dellenbach P, et al. Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. Cancer 1994;73(7):1865-9.
13. Barakat RR, Almadrones L, Venkatraman ES, Aghajanian C, Brown C, Shapiro F, et al. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol 1998;69(1):17-22.
14. Alberts DS, Markman M, Armstrong D, Rothenberg ML, Muggia F, Howell SB. Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Onc 2002;20:3944-6.
15. Markman M, Liu PY, Wilczynski S, Monk BJ, Copeland L, Alberts D. Phase 3 randomized trial of 12 versus 3 months of single-agent paclitaxel in patients with advanced ovarian cancer who attained a clinically defined complete response to platinum/paclitaxel-based chemotherapy: a Southwestern Oncology Group and Gynecologic Oncology Group Trial [abstract 1]. Proc Soc Gynecol Oncol 2002;84:479.
16. Rothenberg ML, Liu PY, Wilczynski S, Hannigan EV, Weiner SA, Weiss GR, et al. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). Gynecol Oncol 2001;82(2):317-22.